Clinical trial
A Prospective, Active Control Open Label, Multicentre Randomized Clinical Trial for Comparison Between BioMime Sirolimus Eluting Stent of Meril Life Sciences and Xience Everolimus Eluting Stent of Abbott Vascular Inc. to Evaluate Efficacy and Safety in Coronary Artery Disease.
NCT02112981 is registered in ClinicalTrials.gov with Meril Life Sciences Pvt. Ltd. as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Prospective, Active Control Open Label, Multicentre Randomized Clinical Trial for Comparison Between BioMime Sirolimus Eluting Stent of Meril Life Sciences and Xience Everolimus Eluting Stent of Abbott Vascular Inc. to Evaluate Efficacy and Safety in Coronary Artery Disease.
- Lead sponsor
- Meril Life Sciences Pvt. Ltd.
- Phase
- Not applicable
- Overall status
- Unknown status
- Start date
- November 5, 2014
- Completion date
- December 1, 2019
- Enrollment
- 256 (actual)
- Sites
- 15
Conditions
As the registry lists them; a condition with its own page is linked.